Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) Short Interest Update

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) was the recipient of a large decrease in short interest in the month of June. As of June 15th, there was short interest totaling 33,404 shares, a decrease of 85.2% from the May 31st total of 225,674 shares. Approximately 6.0% of the shares of the company are sold short. Based on an average daily volume of 313,931 shares, the short-interest ratio is presently 0.1 days.

Institutional Investors Weigh In On Shuttle Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in SHPH. Geode Capital Management LLC purchased a new position in shares of Shuttle Pharmaceuticals in the 4th quarter valued at about $26,000. Boothbay Fund Management LLC acquired a new position in Shuttle Pharmaceuticals during the fourth quarter worth about $37,000. Ikarian Capital LLC purchased a new position in Shuttle Pharmaceuticals in the fourth quarter valued at about $124,000. Finally, Connective Capital Management LLC acquired a new stake in shares of Shuttle Pharmaceuticals during the 3rd quarter valued at approximately $357,000. Institutional investors and hedge funds own 4.58% of the company’s stock.

Shuttle Pharmaceuticals Price Performance

Shares of NASDAQ:SHPH traded up $0.24 during trading on Friday, reaching $4.02. The company had a trading volume of 31,511,150 shares, compared to its average volume of 732,469. Shuttle Pharmaceuticals has a fifty-two week low of $3.16 and a fifty-two week high of $55.90. The stock’s fifty day moving average price is $6.34 and its 200 day moving average price is $11.10. The firm has a market capitalization of $2.57 million, a price-to-earnings ratio of -0.08 and a beta of 0.18.

Shuttle Pharmaceuticals (NASDAQ:SHPH) last posted its quarterly earnings data on Tuesday, March 31st. The company reported $0.60 earnings per share for the quarter.

Analysts Set New Price Targets

Separately, Weiss Ratings lowered shares of Shuttle Pharmaceuticals from a “sell (e+)” rating to a “sell (e)” rating in a research note on Monday, June 15th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Shuttle Pharmaceuticals currently has an average rating of “Sell”.

Shuttle Pharmaceuticals Company Profile

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .